This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Funds: Enter With Care

Investors in biotech have the potential to reap tremendous rewards, but at the same time, the risk can be enormous -- sometimes in the same stock.

For example, an investor in Neurocrine Biosciences (NBIX) could have gotten into the stock below $5 in 1999. Neurocrine topped out at $73 in March of this year.

However, after the FDA failed to approve its insomnia treatment Indiplon and after partner Pfizer (PFE) walked away from the drug, Neurocrine's stock crashed, closing Wednesday at $9.23.

Mutual funds have long been a preferred method for investors to diversify their holdings, but there aren't too many biotech-oriented options. I found 10 funds that invest most of their assets in biotech. Several others have significant exposure to the sector but also invest heavily in medical devices, pharmaceuticals and health care stocks.

Christopher Davis, a fund analyst with Morningstar, suggests one of these broader health care funds for investors who want exposure to biotech. That way, a negative ruling by the FDA on a biotech stock doesn't wreck your portfolio. He points to (PRHSX) T. Rowe Price Health Sciences as one of his favorites. Of the fund's portfolio, 43% is invested in biotech stocks.

"It has a more aggressive approach and looks for faster-growing companies than some of its competitors," he said. As of March 31, four of its top five holdings were biotech -- Gilead Sciences (GILD - Get Report), Amgen (AMGN - Get Report), Genentech (DNA) and Cephalon (CEPH).

That's pretty much what you'll find in most biotech funds, and ETFs for that matter, says Davis, and that is why he recommends avoiding the sector-heavy funds to begin with.

"Chances are, you have exposure to these companies through your other mutual funds," he says. "Every large-cap growth fund owns Amgen and Genentech."

Plus, the mutual funds in the sector tend to be expensive. The ones that aren't appear to have managers with less-than-stellar track records.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AMGN $165.97 1.46%
GILD $100.66 -0.72%
NBIX $42.95 1.08%
AAPL $127.60 2.28%
FB $83.09 2.87%


DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs